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Patients with multiple sclerosis (MS) are at increased risk of infections and related worsening of 
neurological function. Influenza infection has been associated with increased risk of various 
neurological complications. We conducted a population-based registry study to investigate the 
risk of acute hospitalization of MS patients in relation to influenza infection or pandemic 
vaccination in Norway.  
The entire Norwegian population in the years 2008–2014 was defined as our study population 
(N=5 219 296). Information on MS diagnosis, influenza infection and vaccination were provided 
by Norwegian national registries. The self-controlled case series method was used to estimate 
incidence rate ratios (IRRs) with 95 % confidence intervals (95% CI) in defined risk periods. 
6755 MS patients were identified during the study period. Average age at first registration of an 
MS diagnosis was 51.8 years among men and 49.9 years among females (66.9%) The IRR for 
emergency hospitalization among MS patients the first week after an influenza diagnosis was 3.4 
(95% CI: 2.4-4.8). The IRR was 5.6 (95% CI: 2.7-11.3) after pandemic influenza, and 4.8 (95% 
CI: 3.1-7.4) after seasonal influenza. Pandemic vaccination did not influence risk of 
hospitalization (IRR within the first week: 0.7 (95% CI: 0.5-1.0)).  
Among MS patients, influenza infection was associated with increased risk for acute 
hospitalization while no increased risk was observed after pandemic vaccination. Influenza 





Multiple Sclerosis (MS) is a chronic neurological disease with unknown aetiology and 
unpredictable progress. Immunological mechanisms are thought to play an important role in the 
development of MS due to interaction between environmental and genetic risk factors (1). MS 
patients are at increased risk of infections, as disease-modifying therapies may alter the normal 
function of the immune system, or due to underlying changes in immune response (2). Although 
hospitalization rates among MS patients have declined over the past few decades, they remain 
generally higher than in the general population (3-5). MS-related factors and infections are the 
main causes of hospitalizations among MS patients. Increased exacerbation rates in MS patients 
have been reported after influenza illness (6) similar to what has been observed after systemic or 
general viral infections (7-9). Viral infections have been shown to be associated with clinical 
activity of MS (2, 8-10), hence infectious diseases such as influenza may induce relapses and 
cause acute worsening of neurologic function, while vaccination against influenza may prevent 
such adverse events (11, 12).  
Previous studies have mainly focused on influenza vaccination and risk of MS relapse (12, 13). In 
this is the first large register-based study we provide a comprehensive assessment of 
hospitalization risk after specifically influenza infection.  We aim to examine risk of acute 
hospitalization among MS patients up to 3 months following influenza infection and pandemic 
vaccination in a large population-based cohort consisting of 6755 MS patients using nationwide 






The study population consisted of all Norwegian residents during the period 2008 to 2014 (N=5 
219 296) as registered in the Norwegian National Registry. This registry provided information on 
date of birth, date of emigration, and death.  
 
Data sources 
We linked information from several national health registries and databases. All registries contain 
the personal identification number (PIN) which is unique for all citizens, enabling linkage of 
information at the individual level. Information from hospitals and specialist care were obtained 
from the Norwegian Patient Registry (NPR). The NPR is an administrative database linked to the 
reimbursement system with mandatory reporting (14). Diagnoses are reported according to the 
International Classification of Disease, version 10 (ICD-10). The NPR provided information on 
hospitalizations with ICD-10 code G35 (“Multiple sclerosis”).  
Information on influenza diagnoses in primary care was retrieved from the Norwegian 
Directorate of Health which reimburses consultations in emergency outpatient clinics and general 
practice. Influenza diagnoses in primary care were based on the International Classification of 
Primary Care, second edition (ICPC-2) code R80 (“Influenza”). The criteria for using the R80 
code include specific symptoms (e.g. rapid onset, chills/fever and fatigue) and ongoing influenza 
epidemic or influenza in the community. These criteria have been described in detail previously 
(15, 16). In addition to the clinical diagnoses of influenza, we obtained information on pandemic 
influenza infections from the Norwegian Surveillance System for Communicable Diseases to 
which laboratory-confirmed pandemic influenza (but not seasonal influenza) was reported (17).  
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Dates of pandemic vaccinations were obtained from the Norwegian Immunisation Registry (18). 
The Pandemrix® vaccine was offered to the whole population. Notification of pandemic 
influenza vaccinations to the Norwegian Immunisation Registry was mandatory. 
Information on medical prescriptions with MS specific medications dispensed from Norwegian 
pharmacies was provided by the Norwegian Prescription Database (NorPD) from 2004 onwards 
(19). The Anatomical Therapeutic Chemical Classification System (ATC) codes for MS related 
medications were L03AX13  Copaxone® (glatiramer acetate), L04AA27  Gilenya® 
(fingolimod), L04AA31  Aubagio ® (teriflunomide), N07XX09  Tecfidera ® (dimethyl 
fumarate), L03AB07  Avonex®, Rebif® (interferon beta 1a), L03AB08  Betaferon®, Extavia® 
(interferon beta 1b), L03AB13  Plegridy® (peginterferon beta 1 a). Medication with ATC codes 
L04AA23  Tysabri® (natalizumab) and L04AA34   Lemtrada ® (alemtuzumab) are administered 
in hospitals only, and were not included. The NorPD does not hold individual-level information 
on medication administered during hospitalizations. 
 
Definition of MS patients and outcome 
An MS patient was defined by having at least one MS diagnosis registered in specialist care, 
combined with at least one dispensed MS medication (54% of patients). If lacking information on 
medication use, it was required to have at least two registrations of an MS diagnosis (46% of 
patients). Our outcome was defined as acute hospitalizations with an MS diagnosis registered as 




Definition of exposure 
Timing of influenza was examined in relation to hospitalizations with MS. Individuals were 
considered as having an influenza infection if they were diagnosed with influenza in primary 
care, or had a laboratory-confirmed diagnosis. We included information on influenza between 1st 
of January, 2008 (start of follow-up) to April 2014 (end of last influenza season in the study). 
Pandemic influenza was defined as a diagnosis of influenza within the main wave of the H1N1 
influenza pandemic, which in Norway lasted from 1st of October, 2009, to 31st of December, 
2009 (16, 20). Seasonal influenza was defined as a diagnosis of influenza during the influenza 
surveillance periods in Norway (September to May) for the period 2008-2014, excluding the 
pandemic season (from September 2009-May 2010). The season starting September 2014 was not 
included due to short follow-up time. 
The pandemic vaccination campaign began on 19th of October, 2009 and vaccine was offered to 
the whole population free of charge. About 40% of the population was vaccinated and more than 
97% of pandemic vaccinations were administered before 31st of December, 2009 (21).  
 
Statistical analysis 
We applied the self-controlled case series (SCCS) method to estimate incidence rate ratios (IRRs) 
of acute hospitalization with MS diagnosis in various risk periods following a diagnosis of 
influenza infection or vaccination, compared with a background period (22). This method uses 
information from cases only. The strength of this method is that patients serve as their own 
controls, thus confounding from all unmeasured factors that do not vary in the study period is 
eliminated. To avoid surveillance bias, only acute hospitalizations were included. We analysed 
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person-time and timing of hospitalization according to defined time periods (0–1, 2–3, 4–6, 7–9, 
and 10-12 weeks after influenza infection and vaccination). This study included the influenza 
seasons from 1st January, 2008 until 31st of December, 2014. Individuals were followed until 
outcome of interest, death, emigration, or the end of study on 31st of December, 2014, whichever 
occurred first.  
The SCCS approach was applied in four separate models. In model I, we estimated the IRR of 
acute hospitalization among MS patients following a diagnosis of influenza, including any type 
of influenza (any influenza seasons including the pandemic) in the period from 1st of January, 
2008 through 31st of December, 2014. In model II, we estimated IRR of acute hospitalization 
among MS patients only during the main pandemic period (1st of October, 2009 through 31st of 
December, 2009). In model III, the IRR of acute hospitalization among patients was estimated 
following a diagnosis of seasonal influenza infection in the period from 1st of January, 2008 
through 15st May, 2014, excluding the pandemic season (from September 2009-May 2010). In 
model IV, we estimated IRR of acute hospitalization following pandemic vaccination (1st of 
October, 2009 through 31st of April, 2014). IRR was estimated using conditional Poisson 
regression and adjusted for age at hospitalization. 
In an effort to evaluate vaccine safety in patients using different types of MS medications, as 
suggested in previous studies (23, 24), we studied the risk of acute hospitalization among MS 
patients using interferon beta versus non-interferon beta medications. Only MS patients with 
available data on medication were included in this sub-analysis.   
All analyses were performed by using the Stata 13 software (StataCorp. 2013. Stata Statistical 





During 2008–2014, there were 6755 MS patients fulfilling the study criteria. Details on MS 
patients’ characteristics is summarized in Table 1. More women (67.1%) than men were 
registered with MS. Average age at first registration with an MS diagnosis in specialist care was 
51.8 years among men and 49.9 years among women (Figure 1). During the whole study period, 
an influenza diagnosis (seasonal and pandemic combined) was registered for 12.7% of MS 
patients, compared to 12.9% in the general population (Table 2). Overall, 60.7% of MS patients 
received the pandemic vaccine, 57.4%  among men and 62.3% among women.  In the general 
population (individuals without an MS diagnosis), 37.3% were vaccinated with the pandemic 
vaccine, 34.2% among men and 40.4% among women.  
Hospitalizations for MS registered at the same day as the diagnosis of influenza infection was 
high compared with the number of hospitalizations on subsequent days. There were no 
differences in the patterns of hospitalizations before and following pandemic vaccinations (Figure 
2). The IRR of acute hospitalization within one week after an influenza infection (model I) was 
elevated when compared with the other time periods (IRR: 3.4, 95% CI 2.4-4.8) (Table 3). 
Similar findings were observed following pandemic influenza (IRR: 5.6, 95% CI 2.7–11.3) 
(model II) and following seasonal influenza (IRR: 4.8, 95% CI 3.1–7.4) (model III). Our analysis 
evaluating risk of acute hospitalization following pandemic vaccination did not indicate any 
association  at any time point among MS patients (IRR of first week post vaccination: 0.7, 95% 
CI 0.5–1.0) (model IV).  
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In a sub-analysis on risk of acute hospitalization, we compared MS patients using interferon beta 
(2592 patients) with those using non-interferon beta medications (2743 patients). The sub-
analyses yielded similar results as the main analyses.    
 
Discussion 
In this nationwide registry-based study from Norway with individual level data. We observed an 
increased risk of acute hospitalizations with MS within the first week after a diagnosis of 
seasonal or pandemic influenza infection. Pandemic vaccination was not associated with risk of 
acute hospitalization among MS patients.  
 
Strengths and weaknesses 
A major strength of the current study was the availability of information from several 
independent health registries for the complete Norwegian population of more than 5.2 million 
individuals. Further, data on hospitalization, influenza infection and vaccination were 
prospectively collected and recorded independently in separate databases, by different procedures 
and systems, which minimizes the risk of bias due to differential reporting and selection. In 
Norway, the public health care system is financed through governmental funding and all 
hospitalizations are free of charge. MS is a serious condition which is most likely treated in 
hospitals, meaning that information on hospitalization is recorded in the national registries. 
Norwegian health registries and databases have high quality with mandatory reporting and 
minimal loss to follow-up. Another strength of the study was the SCCS method accounting for 
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any factor or characteristic that is not measured but remains constant over the observation period, 
such as genetics, gender, socio-economic status, and lifestyle related factors (25).  
A limitation of this registry-based study is that MS diagnoses  were not validated. Diagnosis of 
MS is a prolonged and challenging process and some patients could be misdiagnosed (26). 
However, a recent validation study on individuals residing in Nordland County in Norway and 
registered with MS in NPR examined the medical record of these individuals and reported that 
91.5% of patients had a confirmed MS diagnosis (27). We believe that our inclusion criteria for 
MS patients (patients with at least two registered diagnoses in specialist care or combination of 
information on diagnoses in specialist care with information on use of MS medications) provided 
a highly reliable identification of MS patients. It is likely that we mostly included patients with 
the relapsing-remitting form with or without secondary progression. Primary progressive MS 
cases accounts for 10 to 15% of the overall population with MS, and these patients may be 
missed or under-represented in our study (6, 28).  
Another weakness of the study is under-reporting of influenza infections in primary care, as only 
those seeking medical attention for influenza are registered. It has been estimated that around 5-
10% of the population is infected with influenza during a regular season (29). During the 2009 
pandemic outbreak less than 4% of the general Norwegian population were diagnosed with 
influenza by a primary care physician (15, 30), however the clinical attack rate of influenza was 
estimated to be approximately 25-30.0% (21). In our study sample, the overall proportion in the 
general population with an influenza diagnosis during the 2009 pandemic outbreak was 2.5%. 
Among MS patients, 4% were diagnosed with pandemic influenza. This supports that MS 
patients were more likely to seek medical help when having influenza, possibly due to the 
seriousness of MS disease and the potential risks associated with having an influenza infection. It 
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could also reflect that MS patients  are more susceptible to influenza than healthy persons (2). 
However, as those with very mild influenza or milder symptoms of MS may have been less likely 
to seek health care, our results may reflect associations with more severe influenza symptoms, or 
associations in patients with less severe MS. Another possible weakness is the potential 
misclassification when using influenza diagnoses from primary care. However, our results 
remained similar to the main analysis when including only cases with laboratory confirmed 
pandemic influenza. 
 
Comparison to the literature 
In accordance with previous studies, there was an increased risk of acute hospitalization among 
MS patients after an influenza diagnosis (6, 7, 9, 10), and no association between pandemic 
vaccination and risk of acute hospitalization was found (11-13). More than six thousand MS 
patients were included in our study, which to our knowledge, is the largest study of seasonal and 
pandemic influenza infection among MS patients. Although we could not identify true MS 
relapses in our data, we believe studying acute hospitalizations may provide an indication for 
worsening MS-related symptoms and relapses. Previous studies did not focus on influenza 
infection and mostly combined several types of infections (7-9), and these were based on 
substantially smaller number of patients, and more selected study populations.  
In previous studies, worsening MS-related symptoms among patients has been reported following 
infection (2, 7, 8). Disease-modifying therapies alter the immune function and may potentially 
increase the risk of infections (2). A population-based Swedish study reported higher hospital 
admission due to infections, including influenza. However, type of influenza and time from 
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infection to hospitalization was not reported (4). A questionnaire study among 233 Dutch MS 
patients, focused on effect of influenza illness and exacerbation of MS symptoms and reported a 
significantly higher rate of exacerbations among MS patients with influenza compared with those 
without influenza (6). Our results support that within the first week following influenza infection, 
the   risk of acute hospitalization was high among MS patients. A longitudinal study in 73 
patients with relapsing-remitting multiple sclerosis assessed the contribution of upper airway 
infections to the risk of exacerbations (7). They reported a significantly increased risk of 
exacerbation 2 weeks before until 5 weeks after the onset of a clinical infection (rate ratio 2.1), 
which also is in accordance with our study.  
Risk of relapse after influenza vaccination (seasonal and pandemic) has been addressed in 
previous studies which are comparable to ours and no change in risk has been reported (11-13). 
We observed that a higher proportion of MS patients were vaccinated against  pandemic 
influenza compared with the general population. MS patients were defined as a risk group and 
were especially recommended pandemic vaccination. In our study, we did not observe any 
change in risk  of acute hospitalization following  pandemic vaccination  which is in concordance 
with previous findings on safety of vaccination. Vaccination is considered as a possible trigger 
for autoimmune disease activity such as MS, however, previous studies as well as the current 
indicate that immunization is safe and may prevent influenza infection and potential 
complications.  For MS patients, type and timing of vaccine (with inactivated influenza virus or 
live attenuated) combined with MS specific medications (interferon-beta versus non-interferon-
beta medications) should be considered carefully (9). In our sub-analyses, stratified by interferon-




Studies of influenza vaccination and risk of relapse have mainly been based on case reports and 
questionnaires. Such study designs are prone to selection/recall bias, and small study samples 
which may undermine the internal and external validity of a study. We acknowledge that 
underreporting of influenza infection is highly likely in our study. However, we utilized timing of 
events in the SCCS model in which patients serve as their own control, which enable us to 
address effects of both seasonal and pandemic influenza. SCCS models, to our knowledge, have 
not previously been applied in this context.  Careful consideration of vaccination, taking the 




In this nationwide registry-based study we found an increased risk for acute hospitalization 
among MS patients within the first week after influenza diagnosis. Influenza infections may 
cause worsening of MS-related symptoms and trigger new relapses and should be prevented 
when possible. We observed no excess risk of acute hospitalization following pandemic 
vaccination. Our study indicates that MS patients could benefit from influenza vaccination, as 
reducing the risk of influenza infections could prevent worsening of MS-related symptoms and 
possibly new relapses.   
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Figure 2: Number of days from influenza diagnosis (top panel), and from day of vaccination (bottom panel) to an acute 
hospitalization, in 14 days prior and 90 days post infection or vaccination. 
19 
 
Table 1: Characteristics of the patients identified with multiple sclerosis (first registration) by year of hospitalizations (2004-2014) in Norway.a 
 
a An MS patient was defined as having at least one registration of an MS diagnosis registered in specialist care, combined with at least one dispensed MS medication. If lacking 
information on medication use, at least two registrations of MS diagnoses were required.
 Year of hospitalization among MS-patients 
 2008 2009 2010 2011 2012 2013 2014 Total 
 N (%) N (%) N (%) N (%) N (%) N (%) N (%) N (%) 
Sex         
 Male 572 (25.6) 398 (17.8) 330 (14.8) 283 (12.7) 247 (11.1) 202 (9.0) 204 (9.1) 2236 (100) 
 Female 1096 (24.3) 827 (18.3) 641 (14.2) 573 (12.7) 530 (11.7) 435 (9.6) 417 (9.2) 4519 (100) 
         
Year of birth         
 1915-1935 135 (41.0) 70 (21.3) 44 (13.4) 33 (10.0) 19 (5.8) 17 (5.2) 11 (3.3) 329 (100) 
 1936-1955 705 (29.3) 435 (18.1) 359 (14.9) 265 (11.0) 259 (10.8) 201 (8.4) 181 (7.5) 2405 (100) 
                1956-1975 674 (23.1) 574 (19.6) 441 (15.1) 386 (13.2) 335 (11.5) 253 (8.7) 260 (8.9) 2923 (100) 
                1976-1995 153 (14.3) 146 (13.6) 123 (11.5) 168 (15.6) 158 (14.7) 161 (15.0) 165 (15.4) 1074 (100) 
                1996-2007 1 (4.2) 0 (0.0) 4 (16.7) 4 (16.7) 6 (25.0) 5 (20.8) 4 (16.7) 24 (100) 
         
Total 1688 (24.7) 1255 (18.1) 971 (14.4) 856 (12.7) 777 (11.5) 673 (9.4) 621 (9.2) 6755 (100) 
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Table 2: Characteristics of the patients identified with Multiple Sclerosis (first registration) by influenza seasons and vaccination in Norway during 2008-2014.a  
a An MS patient was defined as having at least one registration of an MS diagnosis registered in specialist care, combined with at least one dispensed MS medication. If lacking 
information on medication use, at least two registrations of MS diagnoses were required; b All influenza diagnoses for the period 2008-2014; c An influenza diagnosis during the 
main pandemic wave in Norway (October 1st, 2009 to December 31st, 2009); d All influenza diagnoses for the period 2008–2014 excluding the main pandemic period.
 Pandemic vaccination Influenza  
 
MS cases 
  Overall b Pandemic c Seasonal d  
 N (%) N (%) N (%) N (%) N (%) 
Total 4099 (60.7) 857 (12.7) 262 (3.9) 821 (12.6) 6755 (100) 
      
Sex      
 Male 1283 (57.4) 213 (9.5) 83 (3.7) 203 (9.4) 2236 (33.1) 
 Female 2816 (62.3) 644 (14.3) 179 (4.0) 618 (14.2) 4519 (66.9) 
      
Year of birth      
 1915-1935 136 (41.3) 8 (2.4) 13 (4.0) 8 (2.6) 329 (4.9) 
 1936-1955 1576 (65.5) 178 (7.4) 84 (3.5) 168 (7.3) 2405 (35.6) 
                1956-1975 1831 (62.6) 417 (14.3) 132 (4.5) 401 (14.4) 2923 (43.3) 
                1976-1995 542 (50.5) 251 (23.4) 33 (3.1) 245 (23.5) 1074 (15.9) 
                1996-2007 14 (58.3) 3 (12.5) 0 3 (12.5) 24 (0.4) 
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Table 3 Incidence rate ratio (IRR) a of acute hospitalization among Multiple Sclerosis (MS) patients (N=6755) in defined risk windows (period with risk of hospitalization) from 
January 1st, 2008 through December 31st, 2014, with associated 95% confidence interval (CI); estimated by the self-controlled case series method.  
  Influenza  Vaccination 
 Overall (Model I) b Pandemic influenza (Model II) c Seasonal influenza (Model III) d Pandemic vaccination (Model IV) e 
Risk window Number of 
hospitalizations 
IRR (95% CI) Number of 
hospitalizations 
IRR (95% CI) Number of 
hospitalizations 
IRR (95% CI) Number of 
hospitalizations 
IRR (95% CI) 
Background period 6912 - 6363 - 6935 - 6985 - 
2 weeks pre-exposure 16 0.9 (0.5-1.4) 5 1.7 (0.7-4.2) 9 1.1 (0.6-2.1) 51 0.6 (0.5-0.8) 
0-1 week post exposure 32 3.4 (2.4-4.8) 8 5.6 (2.7-11.3) 21 4.8 (3.1-7.4) 32 0.7 (0.5-1.0) 
2-3 weeks post exposure 18 0.9 (0.6-1.5) 3 1.0 (0.3-3.1) 11 1.2 (0.7-2.2) 80 0.9 (0.7-1.1) 
4-6 weeks post exposure 16 0.6 (0.4-1.0) 4 0.9 (0.4-2.6) 7 0.6 (0.3-1.2) 114 0.9 (0.8-1.1) 
7-9 weeks post exposure 24 0.9 (0.6-1.4) 2 0.5 (0.1-1.9) 15 1.3 (0.8-2.1) 123 1.0 (0.8-1.2) 
10-12 weeks post exposure 22 0.8 (0.5-1.2) 3 0.7 (0.2-2.2) 10 0.8 (0.4-1.5) 131 1.0 (0.9-1.2) 
a Analysis were adjusted by age at hospitalization; b Includes all influenza diagnoses occurring during 2008-2014; c Includes diagnoses with pandemic influenza (between October 
1st, 2009 through December 31st, 2009); d Include diagnoses with seasonal influenza occurring during 2008-2014, excluding the pandemic influenza (October 1st, 2009 to December 
31st, 2009); e IRRs were calculated  following pandemic vaccination.  
